Diagonal Bio

Karin Wehlin was elected to the Board of Directors of Diagonal Bio in the spring of 2023, and on November 23, 2023, she was appointed as interim CEO. Karin holds an Executive MBA degree from Lund University and has completed education at INSEAD in Strategy, Innovation, and Leadership. She has over 25 years of experience in senior positions within the Life Science sector, and has served as CEO of Respiratorius AB, LU Food Science AB, and BoMill AB. Karin has also worked as Manager in Corporate Finance and is the founder of EQL Pharma AB, where she served as the Executive Chairman of the board for 10 years.

"Assuming the role of CEO at such a critical juncture in Diagonal Bio's journey is both an honour and a formidable challenge. The past months have been intensely focused on aligning our innovative technology, LAMPlify®, with the market and customer needs. Diagonal Bio’s unique position in the analytical landscape is a testament to our team's ingenuity and dedication. I am eager to continue this journey, driving our strategic goals to fruition and creating substantial value for our customers, partners, and shareholders." – says Karin Wehlin, CEO, Diagonal Bio

“Karin’s expertise and proven track record from life science companies made her the ideal choice for this position. She has already put substantial groundwork for the Company’s strategic initiatives and commercialisation of LAMPlify®. Her formal appointments come as a natural progression of her leadership, underlining the Board of Directors confidence in her vision and execution capabilities. We have the utmost confidence in her ability to lead Diagonal Bio into its next phase of growth and commercialisation.” says Kerstin Jakobsson, Chair of the Board of Directors of Diagonal Bio. “

For additonal information about Diagonal Bio AB, Please contact:

Karin Wehlin, CEO
Phone: +46 703 052 488
E-mail: kw@diagonalbio.com

Kerstin Åkesson Jakobsson
Chair of the Board of Directors
Phone: +46 705 504 540
E-mail: kj@diagonalbio.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
E-mail: ca@skmg.se

This press release contains inside information that Diagonal Bio AB (publ) is required to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication on February 28, 2024, at 17:50 CET.

Diagonal Bio is a Swedish Medtech company founded in 2020 with the vision to limit the spread of infectious diseases worldwide by creating an easy-to-use, cost-efficient, quick, and accurate platform technology based on Diagonal Bio’s patented technology for detection of genetic markers.

At Diagonal Bio we are creating two separate product lines intended for different market segments: LAMPlify® for the less regulated market segments; PANVIRAL® for the in-vitro diagnostic market segments. www.diagonalbio.com